Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Jennifer R Brown, MD, PhD, Jaqueline C. Barrientos, MD, Paul M. Barr, MD, Ian Flinn, MD, PhD, Jan A. Burger, MD, PhD, Zeena Salman, Fong Clow, ScD, Danelle F. James, MD, Thorsten Graef, MD, PhD, Jonathan W. Friedberg, MD, Kanti R. Rai, M.D., Susan O'Brien, MD

Blood (2013) 122 (21): 525.

https://doi.org/10.1182/blood.V122.21.525.525

Published: 2013

Journal Articles

Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model

Shih-Shih Chen, Ph.D., Piers E.M. Patten, MBBCh, PhD, Rita Simone, PhD, Sonia Marsilio, PhD, Jacqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, M.D., Nicholas Chiorazzi, MD

Blood (2012) 120 (21): 316.

https://doi.org/10.1182/blood.V120.21.316.316

Published: 2012

Journal Articles

Gene Expression Profiles Document That Recently- and Previously-Divided CLL Fractions Represent a Continuum but Suggest Differing Modes of Activation for These Fractions in U-CLL and M-CLL

Xiao J. Yan, MD, PhD, Wentian Li, Ph.D., Sophia Yancopoulos, PhD, Igor Dozmorov, PhD, Carlo Calissano, MD, Sonia Marsilio, PhD, Rajendra N Damle, PhD, Steven L. Allen, MD, Jonathan E. Kolitz, MD, Jacqueline C. Barrientos, MD, Kanti R. Rai, M.D., Nicholas Chiorazzi, MD

Blood (2012) 120 (21): 317.

https://doi.org/10.1182/blood.V120.21.317.317

Published: 2012

Journal Articles

The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set

Rainer Claus, MD, Amy S. Ruppert, MAS, David M. Lucas, PhD, Manuela Zucknick, PhD, Laura Z. Rassenti, Ph.D., Andrew Greaves, Donna S. Neuberg, ScD, William G. Wierda, MD, Ph.D., Michael J. Keating, MD, Jennifer R. Brown, MD, PhD, John G Gribben, Kanti R. Rai, M.D., Michael R. Grever, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, Christoph Plass, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 3865.

https://doi.org/10.1182/blood.V120.21.3865.3865

Published: 2012

Journal Articles

Effect of Polymorphisms in p53 Pathway Proteins and B-Chronic Lymphocytic Leukemia Disease Progression,

Hyunjoo Lee, Anthony Liew, Annette Lee, PhD, Shabirul Haque, Ph.D., Jonathan E Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, M.D., Peter Gregersen, MD, Charles C. Chu, Ph.D., Nicholas Chiorazzi, M.D., Patricia Mongini, Ph.D.

Blood (2011) 118 (21): 3888.

https://doi.org/10.1182/blood.V118.21.3888.3888

Published: 2011

Journal Articles

TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity,

Sonal Temburni, MS, Ryon M. Andersen, B.A., Steven L. Allen, M.D., Jaqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D., Rajendra N Damle, PhD

Blood (2011) 118 (21): 3690.

https://doi.org/10.1182/blood.V118.21.3690.3690

Published: 2011

Journal Articles

Co-Culture of CLL Cells with MEACs (Myosin Heavy Chain IIA Exposed Apoptotic Cells) Promotes Viability of Leukemic Clones

Charles C. Chu, Ph.D., Xiaoxuan Cui, M.D., Ph.D., Rosa Catera, Ph.D., Lu Zhang, M.S., Amanda R. Magli, B.S.E., Xiao-Jie Yan, M.D., Ph.D., Jonathan E. Kolitz, MD, Steven L. Allen, M.D., Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D.

Blood (2011) 118 (21): 624.

https://doi.org/10.1182/blood.V118.21.624.624

Published: 2011

Journal Articles

Longitudinal Analyses of CXCR4 dim CD5 br CD19 + Fractions of Chronic Lymphocytic Leukemia Clones Reveal Features Consistent with a Source of Clonal Heterogeneity

Rajendra N Damle, PhD, Carlo Calissano, MD, Sonal Temburni, MS, Ryon M. Andersen, B.A., Steven L. Allen, M.D., Jonathan E. Kolitz, MD, Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D.

Blood (2011) 118 (21): 804.

https://doi.org/10.1182/blood.V118.21.804.804

Published: 2011

Journal Articles

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

Matthew Kaufman, MD, Xiao J. Yan, MD, PhD, Emanuela M. Ghia, PhD, Donna Neuberg, ScD, Laura Z. Rassenti, Ph.D., Kostas Stamatopoulos, MD, Paolo Ghia, MD, PhD, David G Oscier, MD, Frederic Davi, MD, PhD, Richard Rosenquist, MD, PhD, Chrysoula Belessi, MD, Zadie Davis, PhD, Andreas Agathangelidis, Neil Kay, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Kanti R. Rai, M.D., Thomas J. Kipps, M.D., Ph.D, Nicholas Chiorazzi, M.D.

Blood (2011) 118 (21): 288.

https://doi.org/10.1182/blood.V118.21.288.288

Published: 2011

Journal Articles

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Bercedis Peterson, PhD, MS, Kanti R. Rai, M.D., Thomas S. Lin, MD, PhD, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew R Belch, MD, Richard A. Larson, MD, John C. Byrd, MD

Blood (2011) 118 (21): 289.

https://doi.org/10.1182/blood.V118.21.289.289

Published: 2011

Journal Articles

Perspectives Among Primary Care Providers and Hematologist/Oncologists in the Coordination of Care for Patients with Hematologic Malignancies

Haleh Kadkhoda, Clare Karten, MS, Kevin C. Oeffinger, MD, Kanti R. Rai, M.D., S. Frieda Pearce, PhD, Margaret Miller, Jennifer J. Brown, PhD, Nancy Roepke, MS, Ryan Palmore, MA, MS, Jennifer Garick

Blood (2011) 118 (21): 3156.

https://doi.org/10.1182/blood.V118.21.3156.3156

Published: 2011

Journal Articles

Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients

Shih-Shih Chen, Ph.D., Matthew Kaufman, M.D., Angelica Caramanica, Rajendra N Damle, Ph.D., Peter Garofalo, Patricia Ly, Dale Janson, Steven L. Allen, M.D., Jonathan Kolitz, M.D., Linda Quill, Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D.

Blood (2010) 116 (21): 1392.

https://doi.org/10.1182/blood.V116.21.1392.1392

Published: 2010

Journal Articles

Elevated Binding of Chronic Lymphocytic Leukemia Antibody to a Subset of Apoptotic Cells with Exposed Non-Muscle Myosin Heavy Chain IIA Correlates with Poor Patient Outcome.

Charles C. Chu, Ph.D., Rosa Catera, Ph.D., Lu Zhang, M.A., Briana M. Agagnina, Sebastien Didier, M.S., Jonathan E. Kolitz, M.D., Steven L. Allen, M.D., Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D.

Blood (2009) 114 (22): 799.

https://doi.org/10.1182/blood.V114.22.799.799

Published: 2009

Journal Articles

Expression Levels of a Single Gene, Lymphoid Enhancer Binding Factor 1, Discriminates CLL B-Cells from Other B-Cell Malignancies.

Brian A. McCarthy, PhD, Mike Tipping, Ph.D., Xue Ping Wang, Ph.D., Fiona Bennet, Ph.D., Wentian Li, Ph.D., Martin Lesser, Ph.D., Santanu Paul, Ph.D., Erin Boyle, B.S., Carol Moreno, Ph.D., Rosa Catera, Ph.D., Bradley T. Messmer, Ph.D., Steven L. Allen, M.D., Andrew C. Rawstron, M.D., Kanti R. Rai, M.D, Nicholas Chiorazzi, M.D.

Blood (2007) 110 (11): 1113.

https://doi.org/10.1182/blood.V110.11.1113.1113

Published: 2007

Journal Articles

B-CLL Antibodies Encoded by Stereotypic V H 1-69 , D3-16 , and J H 3 Rearrangements Immunoprecipitate Non-Muscle Myosin Heavy Chain IIA.

Charles C. Chu, PhD, Lu Zhang, Katerina Hatzi, Rosa Catera, Ph.D., Steven L. Allen, M.D., Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D.

Blood (2007) 110 (11): 739.

https://doi.org/10.1182/blood.V110.11.739.739

Published: 2007

Journal Articles

GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients.

Robert J. Tressler, PhD, Allison C. Chin, Ph.D., Eric J. Feldman, M.D., Kanti R. Rai, M.D., Doug Kornbrust, Ph.D., Calvin B. Harley, Ph.D., Melissa A. Kelly Behrs, Laurence Elias, MD

Blood (2006) 108 (11): 2595.

https://doi.org/10.1182/blood.V108.11.2595.2595

Published: 2006

Journal Articles

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

Emanuela M. Ghia, PhD, Laura Z. Rassenti, Ph.D., George F. Widhopf, Ph.D., Donna S. Neuberg, Ph.D., Michael J. Keating, M.D., William G. Wierda, M.D., Ph.D., John G. Gribben, M.D., Jennifer R. Brown, M.D., Ph.D., Ian W. Flinn, M.D., Ph.D., Kanti R. Rai, M.D., John C. Byrd, M.D., Neil E. Kay, M.D., Andrew W. Greaves, B.S., Thomas J. Kipps, M.D.,Ph.D.

Blood (2006) 108 (11): 2774.

https://doi.org/10.1182/blood.V108.11.2774.2774

Published: 2006

Journal Articles

B-CLL Antibodies Comprised of Stereotypic V H 1-69, D3-16, and J H 3 Rearrangements Immunoprecipitate Cellular Protein(s).

Charles C. Chu, PhD, Xiao Bo Wang, M.D., Katerina Hatzi, Rosa Catera, Ph.D., Eric Meffre, Ph.D., Maxime Herve, Steven L. Allen, M.D., Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D.

Blood (2006) 108 (11): 2816.

https://doi.org/10.1182/blood.V108.11.2816.2816

Published: 2006

Journal Articles

Genome Analysis of CLL by Representational Oligonucleotide Microarray Analysis (ROMA).

Vladimir D. Grubor, PhD, Jennifer E. Troge, B.S, Jennifer L. Meth, B.S., B. Lakshmi, Ph.D., Boris Yamron, Ph.D., Lisa A. Hufnagel, M.S., Yoon-Ha Lee, Ph.D., Jude T. Kendall, B.S., Deepa Pai, M.S., Annette Lee, Ph.D., Peter Gregersen, M.D., Sophia Yancopoulos, Ph.D., Steven Allen, M.D., Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D., Michael H. Wigler, Ph.D., Diane Esposito, Ph.D.

Blood (2006) 108 (11): 2085.

https://doi.org/10.1182/blood.V108.11.2085.2085

Published: 2006

Journal Articles

Studies on Lymphocytes : VI. Evidence Showing Different Generation Times for Cytologically Different Lymphoid Cell Lines in the Thoracic Duct of the Calf

S. SAFIER, M.D., H. P. WAGNER, M.D., H. COTTIER, M.D., C. R. JANSEN, M.B.,CH.B., KANTI R. RAI, M.D., E. P. CRONKITE, M.D.

Blood (1967) 30 (3): 301–310.

https://doi.org/10.1182/blood.V30.3.301.301

Published: 1967

NARROW

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model

Gene Expression Profiles Document That Recently- and Previously-Divided CLL Fractions Represent a Continuum but Suggest Differing Modes of Activation for These Fractions in U-CLL and M-CLL

The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set

Effect of Polymorphisms in p53 Pathway Proteins and B-Chronic Lymphocytic Leukemia Disease Progression,

TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity,

Co-Culture of CLL Cells with MEACs (Myosin Heavy Chain IIA Exposed Apoptotic Cells) Promotes Viability of Leukemic Clones

Longitudinal Analyses of CXCR4 dim CD5 br CD19 + Fractions of Chronic Lymphocytic Leukemia Clones Reveal Features Consistent with a Source of Clonal Heterogeneity

Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Perspectives Among Primary Care Providers and Hematologist/Oncologists in the Coordination of Care for Patients with Hematologic Malignancies

Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients

Elevated Binding of Chronic Lymphocytic Leukemia Antibody to a Subset of Apoptotic Cells with Exposed Non-Muscle Myosin Heavy Chain IIA Correlates with Poor Patient Outcome.

Expression Levels of a Single Gene, Lymphoid Enhancer Binding Factor 1, Discriminates CLL B-Cells from Other B-Cell Malignancies.

B-CLL Antibodies Encoded by Stereotypic V H 1-69 , D3-16 , and J H 3 Rearrangements Immunoprecipitate Non-Muscle Myosin Heavy Chain IIA.

GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients.

Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.

B-CLL Antibodies Comprised of Stereotypic V H 1-69, D3-16, and J H 3 Rearrangements Immunoprecipitate Cellular Protein(s).

Genome Analysis of CLL by Representational Oligonucleotide Microarray Analysis (ROMA).

Studies on Lymphocytes : VI. Evidence Showing Different Generation Times for Cytologically Different Lymphoid Cell Lines in the Thoracic Duct of the Calf

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only